University of Pennsylvania
Gilead’s Trodelvy approved by EC as first-line treatment for metastatic triple-negative breast cancer
TNBC is the most aggressive type of breast cancer and has historically been difficult to treat
Gilead’s New Drug Application for Yeztugo accepted by US FDA
The investigational once-weekly oral treatment could be the first long-acting pill for HIV prevention
Gilead to acquire Tubulis for up to $5bn
The acquisition builds on Gilead’s oncology pipeline, focused on addressing areas of high unmet need
Gilead to acquire Arcellx in deal worth $7.8bn
The US FDA has accepted a licence application for drug for relapsed/refractory multiple myeloma
Gilead’s Trodelvy plus Keytruda shows positive results in metastatic breast cancer
The combination treatment showed a 35% reduction in the risk of disease progression
Gilead appoints Keeley Wettan as Executive VP, General Counsel, Legal & Compliance
Wettan has served at Gilead for over 14 years
Gilead agrees on affordable medicines plan with US government
The company recently announced a $32bn investment in US R&D and manufacturing
Gilead’s Yescarta shows benefits for patients with large B-cell lymphoma
This is the most common type of non-Hodgkin lymphoma worldwide
Gilead reports Trodelvy breast cancer trial missed primary survival endpoint
The drug treatment is being evaluated in several ongoing phase 3 trials
BMS acquires Orbital Therapeutics in $1.5bn deal
The deal includes several next-gen cell therapy candidates for autoimmune diseases
Gilead shares promising phase 3 results for Trodelvy plus Keytruda in aggressive breast cancer
Triple-negative breast cancer accounts for approximately 15% of all cases of the disease
Gilead’s seladelpar recommended by CHMP to treat primary biliary cholangitis
The rare liver disease affects approximately 15 per 100,000 people in Europe